Agilent Technologies, Inc. (NYSE:A) Jefferies 2024 Global Healthcare Conference June 5, 2024 8:30 AM ET Company Participants Robert McMahon - Senior Vice President and Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson All right, we're good to go. Good morning, everyone. I'm a Tycho Peterson from the life science team here at Jefferies. Pleased to introduce Bob McMahon from Agilent. Robert McMahon Great, thanks. Thanks, Michael. Good to see you. Great to be here ...

Agilent Technologies, Inc. (NYSE:A) Jefferies 2024 Global Healthcare Conference June 5, 2024 8:30 AM ET Company Participants Robert McMahon - Senior Vice President and Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies Tycho Peterson All right, we're good to go. Good morning, everyone. I'm a Tycho Peterson from the life science team here at Jefferies. Pleased to introduce Bob McMahon from Agilent. Robert McMahon Great, thanks. Thanks, Michael. Good to see you. Great to be here ...

Have you assessed how the international operations of Agilent Technologies (A) performed in the quarter ended April 2024? For this scientific instrument maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajecto ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended April 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For transition period from to Commission File Number: 001-15405 AGILENT TECHNOLOGIES, INC. (Exact Name of registrant as specified in its charter) Delaware 77-0518772 (St ...

Agilent Technologies (A) delivered second-quarter fiscal 2024 earnings of $1.22 per share, which beat the Zacks Consensus Estimate by 2.5%. However, the bottom line decreased 4% from the year-ago quarter.Revenues of $1.57 billion lagged the Zacks Consensus Estimate by 0.5%. The top line declined 8.4% on a reported basis and 7.4% on a core basis from the year-ago quarter.The decline was attributed to broad-based weakness across all end markets, especially in the Pharma, Food, and Academic and Government mark ...

Agilent Technologies, Inc. (NYSE:A) Q2 2024 Results Conference Call May 29, 2024 4:30 PM ET Company Participants Parmeet Ahuja - Investor Relations Padraig McDonnell - President & Chief Executive Officer Bob McMahon - Senior Vice President & Chief Financial Officer Phil Binns - President of Agilent Life Sciences & Applied Markets Group Simon May - President of the Agilent Diagnostics and Genomics Group Angelica Riemann - President of Agilent CrossLab Group Conference Call Participants Matt Sykes - Goldman S ...

For the quarter ended April 2024, Agilent Technologies (A) reported revenue of $1.57 billion, down 8.4% over the same period last year. EPS came in at $1.22, compared to $1.27 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.58 billion, representing a surprise of -0.46%. The company delivered an EPS surprise of +2.52%, with the consensus EPS estimate being $1.19.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Agilent Technologies (A) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $1.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.52%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.21 per share when it actually produced earnings of $1.29, delivering a surprise of 6.61%.Over the last four qu ...

Exhibit 99.1 Agilent Reports Second-Quarter Fiscal Year 2024 Financial Results Full-year outlook revised to reflect slower market recovery Announces plan to repurchase $0.75 billion of its common stock by end of fiscal year Board of directors authorizes new $2.0 billion share repurchase program Highlights • Revenue of $1.57 billion, down 8.4% reported and 7.4% core(1) from the second quarter of 2023. • GAAP net income of $308 million; earnings per share (EPS) of $1.05, up 3% from the second quarter of 2023. ...

Core Viewpoint - Agilent Technologies is expected to report a decline in revenues and earnings for the fiscal second quarter of 2024, with specific segments showing varied performance due to macroeconomic factors and regional challenges [1][2][3]. Revenue Expectations - The company anticipates revenues between $1.560 billion and $1.590 billion, reflecting a decline of 9.1-7.4% on a reported basis and 8.4-6.7% on a core basis year-over-year [1]. - The Zacks Consensus Estimate for revenues is set at $1.58 billion, indicating a 7.9% decrease from the previous year's reported figure [1]. Earnings Projections - Non-GAAP earnings are expected to be between $1.17 and $1.20 per share, with the Zacks Consensus Estimate at $1.19 per share, representing a 6.3% decline from the year-ago quarter [1]. Segment Performance - The Cross Lab Group (ACG) is projected to generate $396 million, showing a growth of 2.3% year-over-year, driven by strong portfolio offerings and enterprise service contracts [2]. - The Diagnostics and Genomics Group (DGG) is expected to reach $433 million, reflecting a significant growth of 19.6% from the previous year, supported by demand in the Nucleic Acid Solutions Division and diagnostic tests [3]. - The Life Sciences & Applied Markets Group (LSAG) is forecasted to generate $750 million, indicating a decline of 22.5% year-over-year, impacted by macroeconomic uncertainties and reduced capital equipment spending [3]. Market Challenges - Weakness in the Chemistry & Advanced Materials, Pharma, Food, and Diagnostics and Clinical markets is concerning, with softening demand in China negatively affecting Agilent's performance [3]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for Agilent, as it holds a Zacks Rank of 3 and an Earnings ESP of 0.00% [4].